1. This technology finds that vsRNA1 can inhibit enterovirus protein synthesis. Therefore, vsRNA1 can be an enterovirus inhibitor for antiviral development. 
2. Recombinant peptides derived from FBP1 and FBP2 affect the enterovirus translation machinery. The technology utilizes recombinant polypeptides to establish vaccine cell lines to improve the virus yields required for vaccine production.

1.There are no anti-viral drugs similar to vsRNA1 have been developed. 
2. Engineering host cells to establish useful vaccine cell lines, which can increase enterovirus yields for reducing the cost of vaccine production.

Enterovirus remains an important issue for emerging viral infections worldwide. The small RNA molecule vsRNA1 will be a potential target for anti-enterovirus drug development. Moreover, the engineered cell lines can increase virus yields for vaccine production, and can be applied to virus diagnosis in clinical virology laboratory.